Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.

Mu-Chen ZhangYing FangLi WangShu ChengDi FuYang HeYan ZhaoChao-Fu WangXu-Feng JiangQi SongPeng-Peng XuWei-Li Zhao

Published in: Clinical epigenetics (2020)

CR-CHOP is effective and safe in elderly patients with newly diagnosed DLBCL. Relevance of DEL phenotype and molecular biomarkers on CR-CHOP response warrants further investigation in DLBCL. Trial registration ClinicalTrial.gov, NCT02753647. Registered on April 28, 2016.

Keyphrases

diffuse large b cell lymphoma
newly diagnosed
phase ii study
epstein barr virus
middle aged
open label
community dwelling
locally advanced
clinical trial
phase iii
study protocol
phase ii
randomized controlled trial
single molecule
squamous cell carcinoma
radiation therapy
placebo controlled